Re:Clinician impact and financial cost to NHS of litigation ...
by dm319 on Sunday February 25, 2018 @09:13AM
(#16459027)
And this is the concern of agreements like TTIP, where companies can sue government policies that result in lost revenue.
Obviously there are some benefits - i.e. governments deliberately creating regulations that make competition difficult and essentially recreating protectionism while reaping the rewards of a free market, so I can see why it is a good thing, but it could easily be abused.
Twelve NHS clinical commissioning groups (CCGs) have recommended switching to the cheaper (and just as effective) Avastis drug. But Novartis and Bayer, who market the more expensive Lucentis, have threaten legal action over the use of the cheaper drug.
https://www.theguardian.com/society/2017/nov/01/drug-giants-...